Quercetin activates human Kv1.5 channels by a residue I502 in the S6 segment

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 2, 2009, Pages 154-161

  Yang, Lan ^a   Ma, Ji Hua ^a   Zhang, Pei Hua ^a   Zou, An Ruo ^b   Tu, Dan Na ^b  

^a WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

hKv1.5 channel; I502A; Quercetin; Voltage clamp; Xenopus oocytes

Indexed keywords

AMINO ACID; POTASSIUM CHANNEL KV1.5; QUERCETIN; TANSHINONE IIA;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; MICROELECTRODE; NONHUMAN; OOCYTE; POTASSIUM CURRENT; SITE DIRECTED MUTAGENESIS; STEADY STATE; VOLTAGE CLAMP; WILD TYPE; XENOPUS;

ACTION POTENTIALS; AMINO ACIDS, NEUTRAL; ANIMALS; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HUMANS; HYDROGEN PEROXIDE; ION CHANNEL GATING; ION TRANSPORT; KV1.5 POTASSIUM CHANNEL; MUTAGENESIS, SITE-DIRECTED; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENANTHRENES; PROTEIN BINDING; QUERCETIN; TIME FACTORS; XENOPUS LAEVIS;

EID: 58849109403     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05061.x     Document Type: Article

References (44)

1. Wijffels MC, Kirchhof CJ, Dorland R, Allessie M. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 68.
2. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ. Res. 1997 81 : 512 25.
3. Roden DM, George Jr. AL. Structure and function of cardiac sodium and potassium channels. Am. J. Physiol. 1997 273 : H511 25.
4. + current in canine atrial myocytes. Circ. Res. 2003 93 : 744 51.
5. Gaborit N, Le Bouter S, Szuts V et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol. 2007 582 : 675 93.
6. + channel current. Circ. Res. 1993 73 : 210 16.
7. Snyders DJ, Tamkun MM, Bennett PB. A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J. Gen. Physiol. 1993 101 : 513 43.
8. + current in cultured adult human atrial myocytes. Circ. Res. 1997 80 : 572 9.
9. Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: A novel potassium current family of functional similarity and molecular diversity. Cell Physiol. Biochem. 1999 9 : 217 26.
10. Olson TM, Alekseev AE, Liu XK et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 2006 15 : 2185 91.
11. Baumer AT, Flesch M, Wang X, Shen Q, Feuerstein GZ, Bohm M. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J. Mol. Cell. Cardiol. 2000 32 : 121 30.
12. Becker LB, Hoek TLV, Shao ZH, Li CQ, Schumacker PT. Generation of superoxide in cardiomyocytes during ischemia before reperfusion. Am. J. Physiol. 1999 277 : H2240 6.
13. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ. Res. 1987 61 : 757 60.
14. Ide T, Tsutsui H, Kinugawa S et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 2000 86 : 152 7.
15. Kuzuya T, Hoshida S, Kim Y et al. Detection of oxygen-derived free radical generation in the canine postischemic heart during late phase of reperfusion. Circ. Res. 1990 66 : 1160 5.
16. Mihm MJ, Yu F, Carnes CA et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001 104 : 174 80.
17. Carnes CA, Chung MK, Nakayama T et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ. Res. 2001 89 : E32 8.
18. Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem. Toxicol. 1995 33 : 1061 80.
19. Beecher GR, Warden BA, Merken H. Analysis of tea polyphenols. Proc. Soc. Exp. Biol. Med. 1999 220 : 267 70.
20. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 1993 20 : 21 9.
21. Reiterer G, Toborek M, Hennig B. Quercetin protects against linoleic acid-induced porcine endothelial cell dysfunction. J. Nutr. 2004 134 : 771 5.
22. Murota K, Terao J. Antioxidative flavonoid quercetin: Implication of its intestinal absorption and metabolism. Arch. Biochem. Biophys. 2003 417 : 12 17.
23. Wagner CA, Friedrich B, Setiawan I, Lang F, Broer S. The use of Xenopus laevis oocytes for the functional characterization of heterologously expressed membrane proteins. Cell. Physiol. Biochem. 2000 10 : 1 12.
24. Sigel E, Minier F. The Xenopus oocyte: System for the study of functional expression and modulation of proteins. Mol. Nutr. Food Res. 2005 49 : 228 34.
25. + current in human atrial myocytes. Circ. Res. 1996 78 : 903 15.
26. Fu JJ, Huang HQ, Liu JJ, Pi RB, Chen JW, Liu PQ. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur. J. Pharmacol. 2007 568 : 213 21.
27. + channel. Role of S6 in antiarrhythmic drug binding. Circ. Res. 1996 78 : 1105 14.
28. + channel cloned from human heart. Mol. Pharmacol. 1993 44 : 1240 5.
29. Delpón E, Valenzuela C, Gay P, Franqueza L, Snyders DJ, Tamargo J. Block of human cardiac Kv1.5 channels by loratadine. Voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc. Res. 1997 35 : 341 50.
30. Tosaki A, Engelman DT, Pali T, Engelman RM, Droy-Lefaix MT. Ginkgo biloba extract (EGb 761) improves postischemic function in isolated preconditioned working rat hearts. Coron. Artery Dis. 1994 5 : 443 50.
31. Morales MA, Lozoya X. Calcium-antagonist effects of quercetin on aortic smooth muscle. P1anta. Medical 1994 60 : 313 17.
32. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC. Binding site of a novel Kv1.5 blocker: A 'foot in the door' against atrial fibrillation. Mol. Pharmacol. 2006 70 : 1204 11.
33. + channels. J. Biol. Chem. 2004 279 : 394 400.
34. Eldstrom J, Wang Z, Xu H et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol. Pharmacol. 2007 72 : 1522 34.
35. Shiha CM, Lin H, Liang YC, Lee WS, Bi WF, Juan SH. Concentration- dependent differential effects of quercetin on rat aortic smooth muscle cells. Eur. J. Pharmacol. 2004 496 : 41 8.
36. Cavero I, Mestre M, Guillon JM, Crumb W. Drug that prolong QT interval as unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp. Opin. Pharmacother. 2000 1 : 947 73.
37. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prong the prolong QT interval or induce torsade de points. Drug Saf. 2002 25 : 263 86.
38. Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J. Pharmacol. Exp. Ther. 1995 272 : 184 96.
39. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. 'Early' class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004 110 : 1717 24.
40. Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y. QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. Cardiology 1994 84 : 9 13.
41. + currents. J. Pharmacol. Exp. Ther. 2003 304 : 706 12.
42. Brunner M, Kodirov SA, Mitchell GF et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H194 203.
43. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 1997 80 : 772 81.
44. Lai LP, Su MJ, Lin JL et al. Changes in the mRNA levels of delayed rectifier potassium channels in human atrial fibrillation. Cardiology 1999 92 : 248 55.